US Patent 11926668 Anti-PD-1 antibodies for treatment of lung cancer
Patent 11926668 was granted and assigned to Regeneron Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11926668 Anti-PD-1 antibodies for treatment of lung cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
